Bristol On Track For Growth In 2007 Despite Pargluva Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol is reallocating resources toward existing products and aiming to reach growth targets through other pipeline candidates following the delay and possible termination of muraglitazar.